TNG 462
Alternative Names: TNG-462Latest Information Update: 07 Jul 2025
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Preclinical Cancer
Most Recent Events
- 31 May 2025 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06922591)
- 31 May 2025 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06922591)
- 12 May 2025 Tango Therapeutics plans a registrational trial for Pancreatic cancer (Monotherapy) in 2026